
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Help patients sift through the barrage of misinformation, half-truths, and unproven evidence to set them straight about CBD.






